PortfoliosLab logoPortfoliosLab logo
BBIO vs. MPWR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BBIO vs. MPWR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Monolithic Power Systems, Inc. (MPWR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BBIO achieves a 4.71% return, which is significantly lower than MPWR's 57.89% return.


BBIO

1D
-2.50%
1M
7.47%
6M
3.65%
YTD
4.71%
1Y
69.43%
3Y*
32.71%
5Y*
8.42%
10Y*
ALL TIME*
14.52%

MPWR

1D
8.35%
1M
7.08%
6M
27.30%
YTD
57.89%
1Y
101.90%
3Y*
38.39%
5Y*
26.91%
10Y*
36.06%
ALL TIME*
27.19%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$163.36M$283.28M$252.33M
$1.37B$1.27B$1.35B

BBIO vs. MPWR - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
BBIO
BridgeBio Pharma, Inc.
4.71%178.75%-32.03%429.79%-54.32%-76.54%102.88%14.51%
MPWR
Monolithic Power Systems, Inc.
57.89%54.45%-5.55%79.78%-27.78%35.49%107.49%39.35%

Correlation

The correlation between BBIO and MPWR is 0.21, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.21

Correlation (3Y)
Balances recent behavior with more history.

0.27

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.31

Correlation (All Time)
Calculated using the full available price history since Jun 27, 2019

0.30

Fundamentals

Market Cap

BBIO:

$15.69B

MPWR:

$70.06B

EPS

BBIO:

-$3.74

MPWR:

$16.33

PS Ratio

BBIO:

27.48

MPWR:

21.32

Total Revenue (TTM)

BBIO:

$566.04M

MPWR:

$3.27B

Gross Profit (TTM)

BBIO:

$538.20M

MPWR:

$1.81B

EBITDA (TTM)

BBIO:

-$602.24M

MPWR:

$1.01B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BBIO vs. MPWR — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

BBIO
BBIO Risk / Return Rank: 8585
Overall Rank
BBIO Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
BBIO Sortino Ratio Rank: 8282
Sortino Ratio Rank
BBIO Omega Ratio Rank: 8383
Omega Ratio Rank
BBIO Calmar Ratio Rank: 8989
Calmar Ratio Rank
BBIO Martin Ratio Rank: 8787
Martin Ratio Rank

MPWR
MPWR Risk / Return Rank: 8989
Overall Rank
MPWR Sharpe Ratio Rank: 9191
Sharpe Ratio Rank
MPWR Sortino Ratio Rank: 8686
Sortino Ratio Rank
MPWR Omega Ratio Rank: 8484
Omega Ratio Rank
MPWR Calmar Ratio Rank: 9292
Calmar Ratio Rank
MPWR Martin Ratio Rank: 9090
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

BBIO vs. MPWR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Monolithic Power Systems, Inc. (MPWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BBIOMPWRDifference
Sharpe ratioReturn per unit of total volatility

-0.46

Sortino ratioReturn per unit of downside risk

-0.27

Omega ratioGain probability vs. loss probability

1.28

1.30

-0.01

Calmar ratioReturn relative to maximum drawdown

3.45

3.94

-0.50

Martin ratioReturn relative to average drawdown

7.74

9.44

-1.70

BBIO vs. MPWR - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.44, which is comparable to the MPWR Sharpe Ratio of 1.90. The chart below compares the historical Sharpe Ratios of BBIO and MPWR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BBIO vs. MPWR - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than MPWR's maximum drawdown of -72.27%. Use the drawdown chart below to compare losses from any high point for BBIO and MPWR.


Loading charts...

Drawdown Indicators


BBIOMPWRDifference

Max Drawdown

Largest peak-to-trough decline

-92.80%

-72.27%

-20.53%

Max Drawdown (1Y)

Largest decline over 1 year

-20.25%

-25.99%

+5.74%

Max Drawdown (3Y)

Largest decline over 3 years

-49.08%

-51.65%

+2.57%

Max Drawdown (5Y)

Largest decline over 5 years

-90.72%

-51.65%

-39.07%

Max Drawdown (10Y)

Largest decline over 10 years

-51.65%

Current Drawdown

Current decline from peak

-11.18%

-15.49%

+4.31%

Average Drawdown

Average peak-to-trough decline

-45.08%

-17.71%

-27.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.00%

10.83%

-1.83%

Volatility

BBIO vs. MPWR - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 17.23%, while Monolithic Power Systems, Inc. (MPWR) has a volatility of 18.57%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than MPWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BBIOMPWRDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.23%

18.57%

-1.34%

Volatility (6M)

Calculated over the trailing 6-month period

37.06%

44.07%

-7.01%

Volatility (1Y)

Calculated over the trailing 1-year period

48.65%

54.05%

-5.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

86.05%

54.63%

+31.42%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.29%

47.86%

+35.43%

Dividends

BBIO vs. MPWR - Dividend Comparison

BBIO has not paid dividends to shareholders, while MPWR's dividend yield for the trailing twelve months is around 0.50%.


PositionTTM20252024202320222021202020192018201720162015
BBIO
BridgeBio Pharma, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MPWR
Monolithic Power Systems, Inc.
0.50%0.69%0.85%0.63%0.85%0.49%0.55%0.90%1.03%0.71%0.98%1.26%

Financials

BBIO vs. MPWR - Financials Comparison

This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Monolithic Power Systems, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

BBIO vs. MPWR - Profitability Comparison

The chart below illustrates the profitability comparison between BridgeBio Pharma, Inc. and Monolithic Power Systems, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

BBIO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.

MPWR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Monolithic Power Systems, Inc. reported a gross profit of 541.07M and revenue of 980.64M. Therefore, the gross margin over that period was 55.2%.

BBIO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.

MPWR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Monolithic Power Systems, Inc. reported an operating income of 303.89M and revenue of 980.64M, resulting in an operating margin of 31.0%.

BBIO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.

MPWR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Monolithic Power Systems, Inc. reported a net income of 257.30M and revenue of 980.64M, resulting in a net margin of 26.2%.


Frequently Asked Questions


BBIO and MPWR have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MPWR has higher volatility (18.57%) compared to BBIO (17.23%). In terms of maximum drawdown, BBIO dropped -92.80% vs MPWR's -72.27%.

MPWR currently has the higher Sharpe Ratio (1.90 vs 1.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BBIO and MPWR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer